Clinical Trial Update: CEOP/IVE/GDP Compared With CEOP as the First-line Therapy for Newly Diagnosed Adult Patients With PTCL [Phase 2]

View source ↗

Summary

Phase 2 trial comparing CEOP/IVE/GDP to CEOP as first-line therapy for adults with peripheral T-cell lymphoma subtypes; status currently unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alk-negative Anaplastic Large Cell Lymphoma
• Angioimmunoblastic T-cell Lymphoma
• Enteropathy-associated T-cell Lymphoma
• Hepatosplenic T-cell Lymphoma
• Peripheral T-cell Lymphoma
• Subcutaneous Panniculitis-like T-cell Lymphoma

Drugs mentioned

• CEOP
• CEOP/IVE/GDP

Snippet

Sponsor: Shandong Provincial Hospital | Conditions: Peripheral T-Cell Lymphoma, Not Otherwise Specified, Angioimmunoblastic T Cell Lymphoma | Phase 2 | Status: UNKNOWN